Alcohol can further inflame your liver, making MASH symptoms worse. Learn if and how you can drink with MASH and what medications may cause side effects.

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some ...

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent liver condition to date, with an estimated global prevalence of 38%.1 The progressive and inflammatory stages of ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Search for Symbols, analysts, keywords Log in ESSENCE phase 3 trial of semaglutide showed significant improvements at 72 weeks in adults with MASH, published in NEJM Apr. 30, 2025 5:31 PM ET ...

The bottom line For the millions of Americans living with fatty liver disease, particularly those with the more severe form known as MASH, semaglutide represents a promising new treatment option.

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

Semaglutide is not approved to treat MASH in the U.S. Pharmaceutical maker Novo Nordisk has said it plans to seek regulatory approval for its use in treating liver disease sometime this year.

A weekly dose of semaglutide, a drug used to manage diabetes and weight loss, was effective in 63% of patients at treating a serious form of fatty liver disease, a new study has found.

Adverse events leading to trial discontinuation were 2.6% for the semaglutide group and 3.3% for the placebo group. 1 Semaglutide 2.4 mg is not approved in the US for the treatment of MASH.

RICHMOND, Va., April 30, 2025 (GLOBE NEWSWIRE) -- An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and ...